disorders, including Parkinson's disease, Alzheimer's disease, and prion diseases. [14] [15] [16] [17] Aggregation of misfolded proteins is a common etiology of oxidative stress related to neurodegenerative disorders. 18, 19 Target of rapamycin (TOR) kinase was first identified in yeast as the target of rapamycin, an immunosuppressant. 20, 21 Mammalian target of rapamycin (mTOR) is the mammalian orthologue of TOR 22, 23 and a central regulator of cell growth and metabolism. 24 Similar to TOR in yeast, mTOR functions in two multiprotein complexes: mTORC1 and mTORC2. mTORC1 is sensitive to rapamycin and regulates protein synthesis, nutrient responses, transcription, autophagy, and other cellular processes. [25] [26] [27] mTORC2 contributes to regulation of cell growth, proliferation, and metabolism. 28 Abnormal mTOR activity contributes to the pathogenesis of several neurodegenerative disorders. [29] [30] [31] Experiments using an animal model of tuberous sclerosis (TSC) showed disinhibited mTOR signaling contributing to neuropsychiatric phenotypes, including cognitive deficits and seizures. 32 Studies in AD patients and mouse models of AD have demonstrated activation of the mTOR pathway. 33 Increased phosphorylation of ribosomal protein S6 kinase 1 (S6K1) has been observed in neurons from postmortem samples from patients with AD; moreover, these samples showed increased levels of phospho-mTOR and phospho-4E-BP1, which were correlated with levels of total tau and phospho-tau. 34 [Correction added on 04 April 2017, after first online publication: The word 'reducing' has been deleted from 'Increased phosphorylation of reducing ribosomal protein S6 kinase 1 (S6K1)' in the statement above.] In mouse models of AD, rapamycin protected neurons against tau-induced cell death, 35 while reduced S6K1 expression improved spatial memory and synaptic plasticity. 36 Aberrant mTOR signaling has also been observed in PD. Rapamycin-induced autophagy prevents accumulation of ubiquitinated α-synuclein in α-synuclein overexpression models. 37 The role of mTOR signaling in Huntington's disease (HD) is complex. Overexpression of huntingtin (Htt) protein in striatal neurons was associated with increased basal mTOR activity. 38 In contrast, reduced phosphorylation of ribosomal protein S6 in striatal tissue samples collected from HD patients and HD mice indicated that impaired mTOR activity might contribute to neurodegeneration in HD. 39 mTORC1 inhibitors, such as rapamycin and its analogs, have been used as mTOR-targeted therapeutics in clinical practice. However, rapamycin and inhibitors of Akt (upstream of mTOR) show limited efficacy as inhibitors of mTORC1 signaling. 40, 41 It is widely believed that the incomplete inhibition of mTORC1-mediated phosphorylation following treatment with rapamycin and inhibitors of Akt may be a result of concomitant activation of AKT via the loss of a negative feedback mechanism. 42, 43 Treatment with a combination of mTORC1 and
Akt inhibitors dramatically repressed mTORC1 signaling. 40 Moreover, these inhibitors inhibited phosphorylation of the proline-rich Akt substrate of 40 kDa (PRAS40), which enhanced the repressive function of PRAS40 on mTORC1 signaling. This finding highlights the role of PRAS40 as a critical regulator of mTOR/Akt signaling. PRAS40 is a substrate of Akt, 44 as well as an important substrate and component of mTORC1. 45 In addition, PRAS40 is a direct inhibitor of mTORC1 and an interactive linker between the Akt and mTOR pathways. In this study, we report that mTORC1 inhibitor PRAS40 down-regulated mTOR hyperactivity under stress and alleviated neurotoxic prion peptideinduced apoptosis. This finding suggests that the mTOR pathway, especially PRAS40, may be considered a useful therapeutic target for prion diseases and other neurodegenerative disorders.
| MATERIALS AND METHODS

| Reagents and antibodies
DMEM was purchased from Hyclone (Logan, UT, USA). FBS was purchased from Gibco (Grand Island, NY, USA). Prestained Protein Ladder (BD0027) was purchased from Bioworld Technology (Nanjing, China).
WIP Tissue and Cell Lysis Reagent (C-0013) was purchased from
Beijing Biosynthesis Biotechnology (Beijing, China). SDS-PAGE Sample
Loading Buffer (P0015) was purchased from Beyotime Biotechnology (Shanghai, China). Peroxidase-conjugated AffiniPure Goat Anti-rabbit IgG (H+L; ZB-2301) was purchased from ZSGB Biotechnology (Beijing, China). N-Acetyl-l-cysteine (0108) was purchased from Amresco LLC (Solon, OH, USA). Rapamycin (S1842) and wortmannin (S1952)
were purchased from Beyotime Biotechnology (Shanghai, China). 
| Cell culture
Mouse neuroblastoma N2a cells (Neuro2A cells) were grown in antibiotic-free DMEM (Hyclone) supplemented with 10% FBS (Gibco).
Cells were maintained in a humid incubator (37°C, 5% CO 2 ). The experiments in which the cells were exposed to NAC, rapamycin or wortmannin utilized 1×10 5 cells per well. Cells were obtained from the Cell Culture Center of Xiehe Medical University (Beijing, China).
| Prion protein peptide
The PrP 106-126 peptide (sequence KTNMKHMAGAAAA GAVVGGLG)
was synthesized by Sangon Bio-Tech (Shanghai, China). The purity of the prion peptide was >95% according to the data from the synthesizer. The peptide was dissolved in 0.1 mol/L PBS to a concentration of 1 mmol/L and shaken at 37°C for 1 week to facilitate peptide aggregation. All procedures were performed under sterile conditions. The experiments were conducted with a final peptide concentration of 100 μmol/L.
| Assay of intracellular reactive oxygen species (ROS)
ROS abundance was measured using a ROS assay kit (Beyotime, China) according to the reagent protocol included by the manufacturer. Briefly, the growth medium was decanted from Neuro2A cells, after which the cells were washed with PBS, followed by incubation 
| Plasmids and transfection
pRK5-HA-PRAS40 (Addgene plasmid #15481) and pLKO.1-mPRAS40
(Addgene plasmid #15480) were gifts from Do-Hyung Kim. For the transfection, 2500 ng DNA was added to 1×10 6 adherent cells in a six-well plate, after which 6 μL of Lipofectamine 2000 was diluted in 150 μL Opti-MEM medium and incubated for 5 minutes with the diluted DNA at room temperature.
| Measurement of apoptosis by flow cytometry
Apoptotic cell counting was conducted using the Annexin V-FITC Apoptosis Detection Kit (A211-01; Vazyme Biotech Co., Ltd., Nanjing, China). Apoptosis analysis was performed as described previously. 
| Western blotting
Western blotting was performed as described previously. 48 Briefly, equal amounts of protein (40 μg in each lane) were separated by SDS-PAGE on 12% gels, after which the separated proteins were transferred onto a nitrocellulose membrane. Nonspecific binding sites were blocked by incubating the membrane with BSA Blocking Buffer (cw0054, pH 7.5; CWBIO, Beijing, China).
| Statistical analysis
All assays were performed on three separate occasions. Data are expressed as mean±SD. All comparisons of parametric data were performed using Student's t test or one-way ANOVA followed by Tukey's multiple comparison test. Statistical analysis was conducted using SPSS (version 13.0; IBM Co., Armonk, NY, USA), GraphPad Prism 5 (GraphPad Inc., La Jolla, CA, USA), and ImageJ (National Institutes of Health, Bethesda, MD, USA). The threshold for statistical significance was P<.05.
| RESULTS
| Activation of mTOR in N2a cells upon exposure to PrP
106-126
Several investigations have shown that abnormal mTOR activity contributes to the pathogenesis of neurodegenerative disorders and leads to cognitive deficits. 29, 30, 32, 33, 38 Moreover, hyperactive mTORC1 signaling has been reported to sensitize cells to apoptosis. -treatment. Activation of the mTOR pathway after exposure to PrP 106-126 was at least partially due to ROS production.
| Overexpression of PRAS40 inhibited neuronal apoptosis induced by neurotoxic prion peptide
We hypothesized that mTOR hyperactivation contributes to neuronal apoptosis induced by aggregation of misfolded proteins. Thus, 
β-actin
PrP106-126
we overexpressed PRAS40 to determine whether its neuroprotective effect against neurotoxic prion peptide-induced neuronal apoptosis is mediated by its direct inhibitory effect on TORC1. Figure 3B ), confirming that the mTOR pathway was activated by PrP 106-126 . In summary, the mTOR pathway was activated after exposure to PrP 106-126 , and this activation can be inhibited by PRAS40 overexpression or rapamycin treatment.
| PRAS40 alleviates PrP
106-126 -induced neuronal apoptosis via mTOR-AKT activation
Experiments were conducted to elucidate the manner in which mTOR promotes neuronal apoptosis and assess the link between apoptosis and mTOR. One likely mechanism for the link between apoptosis and mTOR is a negative feedback loop (NFL), in which mTORC1 activation inhibits PI3K-Akt signaling; 51, 52 this NFL is mediated via phosphorylation of the insulin receptor substrate (IRS) by S6K1. Furthermore, activation of Akt prevents apoptosis. 53 In cancer cells, suppression of apoptosis via Akt inhibits the activity of transcription factors forkhead box O1 and forkhead box O3A (FoxO1/FoxO3A). 54 As a key molecular link between mTORC1 and apoptosis, Akt activation was analyzed. Akt activation can be inhibited by mTORC1 activation, so we determined whether Akt was activated after PRAS40 overexpres- 
| DISCUSSION
In this study, we found that PRAS40-mediated mTOR signaling is an 
| Misfolded proteins, oxidative stress and apoptosis
Misfolded proteins evoke oxidative stress, which contributes to the development of apoptotic neuronal cell death and neuronal dysfunction. [14] [15] [16] [17] PrP 106-126 induced mitochondrial dysfunction and apoptosis in N2a cells, consistent with our previous work.
55,56
Apoptosis is a complex process of programmed cell death and destruction that is involved in many diseases and disorders. 57 In many types of cancer, resistance to apoptosis is a major driver of pathogenesis. Therefore, modulation of aberrant apoptosis is an attractive anticancer therapeutic strategy. 58, 59 Under inflammatory conditions, a prolonged neutrophil lifespan due to delayed apoptotic death may be needed to protect the host from pathogens. [60] [61] [62] However, neurons do not divide, so promotion of neuron survival is extremely important in patients with neurodegenerative disorders.
| mTOR activation in neurodegenerative disorders
mTORC1 is activated under oxidative stress mainly because of inactivation of the TSC1-TSC2 complex. 63 Growth factors and hormones such as insulin stimulate the mTORC1 pathway. In addition, mTORC1
is activated by G-protein Rheb and inhibited by TSC2-mediated inhibition of Rheb. 64 Under arsenite stress, TSC2 down-regulation is associated with S6K1 phosphorylation. 51 Therefore, oxidative stress activates mTORC1 mainly by inhibiting TSC2 activation, abolishing the inhibitory effect of TSC2 on mTORC1.
Abnormal mTOR activity contributes to the pathogenesis of neurodegenerative disorders and leads to cognitive deficits. 29, 30, 32, 33, 38 Moreover, hyperactive mTORC1 signaling has been reported to sensitize cells to apoptosis. 49, 50 In this study, neurotoxic prion peptideinduced neuronal apoptosis was inhibited by abolishing ROS-induced cellular stress or inhibiting mTORC1 activation. These results are consistent with the studies described above.
The reason why mTOR activation is needed under oxidative stress is interesting. We supposed that, as a central regulator of growth and metabolism, the mTOR pathway is required for synthesis and 
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neurodegeneration. However, some findings suggest that enhancing the activity of mTORC1 is neuroprotective. 39 These results contradict the conventional view that inhibition of mTORC1 is neuroprotective. 38, 66, 67 Davidson et al. 39 showed that mTORC1 activity was reduced in their HD model, and found that reinstating aberrant mTORC1 activity improved disease phenotypes. However, in other studies, 36 suppressing mTORC1 under conditions associated with hyperactive mTORC1 improved disease phenotypes. We believe that, 
| PRAS40 and mTOR inhibition
PRAS40 is an important substrate and inhibitory component of mTORC1. Phosphorylation of PRAS40 results in disassociation of PRAS40 from mTORC1, which relieves its inhibitory constraint on mTORC1 activity. 46, 68 We found that PRAS40 down-regulated mTOR hyperactivity under prion peptide-induced neuronal toxicity and alleviated neuronal apoptosis. Cells were exposed to rapamycin to compare its effects with those of PRAS40. Rapamycin is a classical inhibitor of mTORC1. 40, 69, 70 Rapamycin consistently inhibited mTORC1 and attenuated apoptosis. These findings support the role of PRAS40 in protecting neurons from neurotoxic prion peptide-induced apoptosis.
Inhibition of mTORC1 by PRAS40 releases the negative feedback loop, leading to activation of Akt. Consistent with this role, increased Akt phosphorylation has been observed frequently following treatment with rapamycin, 71 but not following exposure to dual mTORC1/ mTORC2 inhibitors. 72 Moreover, impaired mTORC2 complex integrity may inhibit Akt signaling. 73 Therefore, we used PRAS40 as a specific inhibitory protein to mediate mTORC1 activation.
| FOXO transcription factors and Akt signaling
Forkhead box O (FOXO) transcription factors play a critical role in many cellular processes, including the cell cycle, metabolism, apoptosis, and resistance to oxidative stress. 74, 75 The FOXO family (FOXO1, 3, 4, and 6) can respond to insulin/growth factors and is negatively regulated by PI3K-Akt signaling. 76 Akt-mediated phosphorylation of FOXOs inhibits their transcriptional activity. 74 In the presence of growth factors, FOXOs are sequestered by the PI3K-Akt pathway in the cytoplasm.
FOXOs translocate into the nucleus and transcribe target genes when
Akt is inactive in the absence of growth factors. 77 In our study, FoxO1/ O3A phosphorylation was induced following PRAS40 overexpression Apoptosis ( Figure 4A ), which shows that the activity of these transcription factors was inhibited by Akt activation, thus facilitating neuronal survival under oxidative stress-induced apoptosis.
Many studies have demonstrated that the Akt pathway supports neuronal survival. 53, 78 In this study, PRAS40 down-regulated mTOR hyperactivity and induced AKT activation via a negative feedback mechanism. PRAS40 overexpression inhibited apoptosis via Akt activation, but wortmannin abolished the reduction in apoptosis associated with PRAS40 overexpression. This finding confirmed the role of PRAS40 in Akt phosphorylation.
| Negative feedback loop between mTOR and Akt signaling
Akt activation prevents apoptosis. In other words, Akt activation activates the mTOR pathway.
However, upon mTORC1 activation, negative feedback loops inhibit PI3K-Akt signaling. 52 Phosphorylation of AKT is mediated by mTORC1/S6K1, mTORC2, and other pathways. 73, 80 These negative feedback loops are the reason that mTORC1 hyperactivation induces apoptosis, although Akt is known to prevent apoptosis ( Figure 5 ).
Rapamycin induced activation of Akt via a feedback loop and
weakened the effect of mTOR inhibition. Therefore, we focused on PRAS40 and the pivotal role of PRAS40 in the regulation of aberrant mTOR signaling.
We believe that the site where stimulation acts in the loop is important. Persistent stimulation by oxidative stress enhances mTORC1 hyperactivation and induces apoptotic neuronal signaling and neurotoxicity. Thus, PRAS40 inhibits mTORC1 hyperactivation and plays a key role in protecting neurons from neurotoxic prion peptide-induced apoptosis. These findings suggest that the mTOR pathway, and PRAS40 in particular, should be exploited as a therapeutic target for prion diseases and other neurodegenerative disorders.
